What is HC Wainwright’s Estimate for BCYC FY2029 Earnings?

Bicycle Therapeutics plc (NASDAQ:BCYC) – Analysts at HC Wainwright boosted their FY2029 earnings per share estimates for shares of Bicycle Therapeutics in a research note issued to investors on Thursday, May 1st. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $1.22 for the year, up from their prior estimate of $1.20. HC Wainwright has a “Buy” rating and a $33.00 price target on the stock. The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.06) per share.

BCYC has been the topic of a number of other reports. Royal Bank of Canada reduced their price target on shares of Bicycle Therapeutics from $35.00 to $32.00 and set an “outperform” rating on the stock in a research report on Friday, May 2nd. Morgan Stanley set a $17.00 target price on shares of Bicycle Therapeutics and gave the company an “equal weight” rating in a report on Monday. Stephens reiterated an “equal weight” rating and issued a $15.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd. B. Riley reduced their price objective on Bicycle Therapeutics from $17.00 to $14.00 and set a “neutral” rating on the stock in a research note on Friday, May 2nd. Finally, JMP Securities lowered their target price on Bicycle Therapeutics from $26.00 to $22.00 and set a “market outperform” rating for the company in a research note on Friday, May 2nd. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Bicycle Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $25.00.

Bicycle Therapeutics Trading Down 18.0 %

Shares of BCYC opened at $7.43 on Monday. Bicycle Therapeutics has a twelve month low of $6.10 and a twelve month high of $28.67. The firm has a market capitalization of $514.17 million, a P/E ratio of -2.26 and a beta of 1.60. The stock’s fifty day simple moving average is $8.59 and its 200 day simple moving average is $14.13.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Thursday, May 1st. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business had revenue of $9.98 million for the quarter, compared to analysts’ expectations of $8.67 million.

Hedge Funds Weigh In On Bicycle Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Barclays PLC boosted its position in Bicycle Therapeutics by 878.3% during the 4th quarter. Barclays PLC now owns 2,612 shares of the company’s stock worth $37,000 after acquiring an additional 2,345 shares during the period. Avior Wealth Management LLC purchased a new stake in shares of Bicycle Therapeutics in the fourth quarter worth approximately $57,000. GAMMA Investing LLC boosted its holdings in shares of Bicycle Therapeutics by 879.5% during the first quarter. GAMMA Investing LLC now owns 8,982 shares of the company’s stock worth $76,000 after purchasing an additional 8,065 shares during the period. Exchange Traded Concepts LLC grew its position in Bicycle Therapeutics by 90.3% during the first quarter. Exchange Traded Concepts LLC now owns 12,764 shares of the company’s stock valued at $108,000 after purchasing an additional 6,057 shares in the last quarter. Finally, Cerity Partners LLC acquired a new position in Bicycle Therapeutics in the 1st quarter valued at approximately $113,000. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.